Cargando…

Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter

The coronavirus disease 2019 (COVID-19) pandemic has a serious impact on health and economics worldwide. Even though the majority of patients present with moderate and mild symptoms, yet a considerable portion of patients need to be treated in the intensive care unit. Aside from dexamethasone, there...

Descripción completa

Detalles Bibliográficos
Autores principales: Pape, Anke, Kielstein, Jan T., Krüger, Tillman, Fühner, Thomas, Brunkhorst, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046512/
https://www.ncbi.nlm.nih.gov/pubmed/33870077
http://dx.doi.org/10.1055/s-0041-1727121
_version_ 1783678866490916864
author Pape, Anke
Kielstein, Jan T.
Krüger, Tillman
Fühner, Thomas
Brunkhorst, Reinhard
author_facet Pape, Anke
Kielstein, Jan T.
Krüger, Tillman
Fühner, Thomas
Brunkhorst, Reinhard
author_sort Pape, Anke
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic has a serious impact on health and economics worldwide. Even though the majority of patients present with moderate and mild symptoms, yet a considerable portion of patients need to be treated in the intensive care unit. Aside from dexamethasone, there is no established pharmacological therapy. Moreover, some of the currently tested drugs are contraindicated for special patient populations like remdesivir for patients with severely impaired renal function. On this background, several extracorporeal treatments are currently explored concerning their potential to improve the clinical course and outcome of critically ill patients with COVID-19. Here, we report the use of the Seraph 100 Microbind Affinity filter, which is licensed in the European Union for the removal of pathogens. Authorization for emergency use in patients with COVID-19 admitted to the intensive care unit with confirmed or imminent respiratory failure was granted by the U.S. Food and Drug Administration on April 17, 2020. A 53-year-old Caucasian male with a severe COVID-19 infection was treated with a Seraph Microbind Affinity filter hemoperfusion after clinical deterioration and commencement of mechanical ventilation. The 70-minute treatment at a blood flow of 200 mL/minute was well tolerated, and the patient was hemodynamically stable. The hemoperfusion reduced D-dimers dramatically. This case report suggests that the use of Seraph 100 Microbind Affinity filter hemoperfusion might have positive effects on the clinical course of critically ill patients with COVID-19. However, future prospective collection of data ideally in randomized trials will have to confirm whether the use of Seraph 100 Microbind Affinity filter hemoperfusion is an option of the treatment for COVID-19.
format Online
Article
Text
id pubmed-8046512
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-80465122021-04-15 Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter Pape, Anke Kielstein, Jan T. Krüger, Tillman Fühner, Thomas Brunkhorst, Reinhard TH Open The coronavirus disease 2019 (COVID-19) pandemic has a serious impact on health and economics worldwide. Even though the majority of patients present with moderate and mild symptoms, yet a considerable portion of patients need to be treated in the intensive care unit. Aside from dexamethasone, there is no established pharmacological therapy. Moreover, some of the currently tested drugs are contraindicated for special patient populations like remdesivir for patients with severely impaired renal function. On this background, several extracorporeal treatments are currently explored concerning their potential to improve the clinical course and outcome of critically ill patients with COVID-19. Here, we report the use of the Seraph 100 Microbind Affinity filter, which is licensed in the European Union for the removal of pathogens. Authorization for emergency use in patients with COVID-19 admitted to the intensive care unit with confirmed or imminent respiratory failure was granted by the U.S. Food and Drug Administration on April 17, 2020. A 53-year-old Caucasian male with a severe COVID-19 infection was treated with a Seraph Microbind Affinity filter hemoperfusion after clinical deterioration and commencement of mechanical ventilation. The 70-minute treatment at a blood flow of 200 mL/minute was well tolerated, and the patient was hemodynamically stable. The hemoperfusion reduced D-dimers dramatically. This case report suggests that the use of Seraph 100 Microbind Affinity filter hemoperfusion might have positive effects on the clinical course of critically ill patients with COVID-19. However, future prospective collection of data ideally in randomized trials will have to confirm whether the use of Seraph 100 Microbind Affinity filter hemoperfusion is an option of the treatment for COVID-19. Georg Thieme Verlag KG 2021-04-14 /pmc/articles/PMC8046512/ /pubmed/33870077 http://dx.doi.org/10.1055/s-0041-1727121 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pape, Anke
Kielstein, Jan T.
Krüger, Tillman
Fühner, Thomas
Brunkhorst, Reinhard
Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
title Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
title_full Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
title_fullStr Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
title_full_unstemmed Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
title_short Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter
title_sort treatment of a critically ill covid-19 patient with the seraph 100 microbind affinity filter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046512/
https://www.ncbi.nlm.nih.gov/pubmed/33870077
http://dx.doi.org/10.1055/s-0041-1727121
work_keys_str_mv AT papeanke treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter
AT kielsteinjant treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter
AT krugertillman treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter
AT fuhnerthomas treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter
AT brunkhorstreinhard treatmentofacriticallyillcovid19patientwiththeseraph100microbindaffinityfilter